We are delighted to share a new #podcast, “Improving the status quo – can severe asthma be better treated?” on @The Spectator Briefings!
We chat about the experiences of Gabby Perry, a student with severe #asthma, and the dual-edged swords that are steroids. Along with Gabby, Syed Ali, medical affairs...
Read moreCONQUEST quality standards: for the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care
The CONQUEST Quality Standards (QS) aim to enhance care for COPD patients at a higher, yet modifiable, risk of COPD exacerbations, increased morbidity and mortality...
Read more
Evaluating the impact of targeted, risk-based management in patients with modifiable high-risk COPD
The Observational and Pragmatic Research Institute is proud to announce the launch of the Pragmatic Evaluation of an Improvement Program for People Living with...
Read more
COVID-19 Quality Improvement Programme for Primary Care
New COVID-19 quality improvement programme available to GP practices across the United Kingdom First-of-its-kind quality improvement programme to exclusively focus on...
Read more
Using systemic steroids to manage asthma
Bleecker ER, Menzies-Gow A, Price D, Bourdin A, Sweet S, Martin A, Alacqua M, Tran TN. Systematic Literature Review of Systemic Corticosteroid Use for Asthma...
Read more
Improving patient care for children with asthma: PeARL’s first steps
Mathioudakis AG, Custovic A, Deschildre A, Price D et al. Research priorities in pediatric asthma: Results of a global survey of multiple stakeholder groups by the...
Read more
Aiding physicians in prescribing the right inhaler
World-leading Singapore research institute, the Observational Pragmatic Research Institute (OPRI), is the largest contributor to the global understanding of inhalers...
Read more
Management of Asthma in Different Phenotypes – Presented at APSR 2019
Professor David Price recently spoke about the management of asthma in different phenotypes at the Asian Pacific Society of Respirology’s Asthma Symposium 2019. While...
Read more
Inhaled Corticosteroids In COPD And Onset Of Type 2 Diabetes And Osteoporosis: A Matched Cohort Study
A study by OPRI published in NPJ Primary Care Respiratory Medicine found a link between ICS therapy for patients with COPD and the onset of type 2 diabetes and...
Read more
Describing the GOLD Group Distribution and Appropriateness of Therapy in Patients with COPD.
A study by OPRI describing in details the GOLD group distribution in patients with COPD who started their initial treatment and those with established COPD has been...
Read more
Leveraging Randomized Clinical Trials to Generate Real-World Evidence for Regulatory Purposes
Washington, 11th July 2019 – Professor David Price, head of The Observational & Pragmatic Research Institute (OPRI; Singapore) and Optimum Patient Care (OPC...
Read more
Management of Community-Acquired Pneumonia: An Observational Study in UK Primary Care
A study to assess the frequency of CRB65 scoring in patients diagnosed with community-acquired pneumonia (CAP) in primary care has been recently published in the Dove...
Read more
Omalizumab in the Era of Precision Medicine
Allergic allergy has been increasing in Hong Kong given evolutionary and genetic or environmental factors. Omalizumab, or anti-IgE, is a monoclonal antibody approved...
Read more
Primary Care Respiratory Society Conference 2019 🗓
The PCRS Respiratory Conference is the UK’s leading respiratory conference. Its aim is to inspire delegates to discover new ways of working with patients and...
Read more
Boehringer Ingelheim and Optimum Patient Care Launch First US Primary Care Patient Registry to Improve COPD Care and Outcomes
First-of-its-kind registry to exclusively focus on chronic obstructive pulmonary disease (COPD) treatment by primary care physicians Registry will track 3,000...
Read more
Could heart drug help lung disease patients?
Drugs traditionally used to treat blood pressure and heart disease are to be given to lung disease patients to see if they can be beneficial, in a trial coordinated...
Read more
Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations
A CRN supported Respiratory Disorders trial (TWICS), which investigated whether taking a low-dose theophylline tablets in addition to inhaled corticosteroids would...
Read more
Does changing inhaler device change asthma outcomes?
Singapore, 5th October 2018. Most people with asthma rely on inhaled asthma medication to control their symptoms. Inhaler devices are available as either dry powder...
Read more
Predictive utility of database-derived asthma exacerbation and asthma control measures in a UK primary care database
Database-derived measures of asthma control was predictive of asthma treatment response and future asthma exacerbation. This study validates the usage of database...
Read more
COPD patient subset gains no benefit from low-dose theophylline
AT ATS 2018 SAN DIEGO – For people with COPD at high risk of exacerbation, the addition of low-dose theophylline to inhaled corticosteroids conferred no overall...
Read more
Hay fever sufferers may not be picking the right drugs to treat symptoms
A study in The Journal of Allergy and Clinical Immunology: In Practice found the majority of surveyed people with hay fever were not picking optimal over-the-counter...
Read more
Breathing exercises help asthma patients with quality of life
Southampton, 12th December, 2017. A study led by the University of Southampton has found that people who continue to get problems from their asthma, despite receiving...
Read more
REcognise Asthma and LInk to Symptoms and Experiences (REALISE)
REALISE survey aimed to assess levels of asthma control and patient-reported asthma control Factor analysis identified distinct patient clusters with varying...
Read more
Blood eosinophil counts help predict COPD exacerbation risk in ex-smokers
Singapore, 13th November, 2017. Chronic obstructive pulmonary disease (COPD) is an important public health challenge as it is a major cause of chronic morbidity and...
Read more
Nicotine replacement therapy causes an increase in cardiovascular events during a 52-week follow-up period
Treatment with NRT during a brief, 4-week, follow-up period does not appear to put patients at risk of cardiovascular disease. However, at 52 weeks, there was an...
Read more
To fine or extrafine: which ICS formulation has the better dose response in patients with asthma?
Dose-dependent reduction in asthma exacerbations for patients treated with extrafine-particle inhaled corticosteroids in an adult UK asthma population; a result not...
Read more
International study highlights importance of inhaler technique on asthma patient outcomes
International CRITIKAL Study1 is one of the largest to investigate inhaler technique and the first to analyse the direct associations between specific inhaler errors...
Read more